NasdaqCM - Delayed Quote USD
Marker Therapeutics, Inc. (MRKR)
1.1100
-0.0200
(-1.77%)
At close: May 16 at 4:00:01 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Juan F. Vera M.D. | Co-Founder, CEO, President, Treasurer, Secretary & Director | 400k | -- | 1980 |
| Ms. Elizabeth Donnelly | Director of Administration | -- | -- | -- |
| Dr. Maria-Bernadette Madel Ph.D. | Director of Corporate Operations & External Communications | -- | -- | 1990 |
| Mr. Edmund Cheung | Vice President of Human Resources | -- | -- | -- |
| Patricia Allison | Head of Clinical Operations | -- | -- | -- |
| Ms. Mary Newman Ph.D. | Head of Regulatory Affairs | -- | -- | 1959 |
| Dr. F. Andrew Dorr M.D. | Chief Medical Officer | -- | -- | 1953 |
| Dr. Robert Z. Florkiewicz Sr., Ph.D. | Senior Director of Molecular Biology & Virology | -- | -- | -- |
Marker Therapeutics, Inc.
2450 Holcombe Blvd
MS: BCM251
Houston, TX 77021
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 5
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Corporate Governance
Marker Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 12, 2025 at 10:59 AM UTC - August 18, 2025 at 12:00 PM UTC
Marker Therapeutics, Inc. Earnings Date
Recent Events
Related Tickers
ARTL Artelo Biosciences, Inc.
0.9200
-2.13%
ERNA Ernexa Therapeutics Inc.
0.2240
-4.27%
LYEL Lyell Immunopharma, Inc.
0.4150
+3.31%
SNPX Synaptogenix, Inc.
2.1600
-2.70%
BOLT Bolt Biotherapeutics, Inc.
0.2930
-7.57%
AKTX Akari Therapeutics, Plc
1.2700
+3.25%
PHGE BiomX Inc.
0.5400
-4.20%
MGNX MacroGenics, Inc.
1.5800
+2.60%
ZYME Zymeworks Inc.
11.71
+1.56%
MBIO Mustang Bio, Inc.
1.1200
-0.88%